Market Overview:
The global β adrenoceptor agonists market is expected to register a CAGR of 5.8% during the forecast period, 2018-2030. The market growth can be attributed to the increasing prevalence of chronic heart failure, myocardial infarction, and postoperative hypotension. In addition, rising awareness about asthma and other respiratory disorders is also propelling the demand for β adrenoceptor agonists globally. Based on type, the global β adrenoceptor agonists market is segmented into isoprenaline, dobutamine, salbutamol, terbutaline salmeterol formoterol pirbuterol). Isoprenaline held a dominant share in 2017 and is expected to maintain its lead throughout the forecast period. This can be attributed to its high efficacy in treating various cardiac conditions such as chronic heart failure and myocardial infarction. Salbutamol held second largest share in 2017 due to its widespread use for treating bronchial asthma and other respiratory disorders. Based on application, the global β adrenoceptor agonists market is segmented into chronic heart failure (CHF), myocardial infarction (MI), postoperative hypotension (POH), bronchial asthma (BA), asthmatic bronchitis (AB), emphysema (EMPH) others).
Product Definition:
β adrenoceptor agonists are a type of drug that activate the β adrenergic receptors in the body. This class of drugs is used to treat a variety of conditions, including asthma, chronic obstructive pulmonary disease (COPD), and heart failure.
Isoprenaline:
Isoprenaline, also known as 2-isobutylpiperidine, is an organic compound that is classified as a piperidine. Isoprenaline has a molecular formula of C3H5N3 and a molecular weight of 93.1.
Dobutamine:
Dobutamine is a non-glucoseotic compound that works as an agonist for the β adrenoceptor. It is used in the treatment of cardiac failure and pulmonary hypertension. The drug has no known street value and its usage is limited to hospital settings, therefore it cannot be purchased off the shelf like other drugs such as epinephrine (Adrenaline) or norepinephrine.
Application Insights:
The chronic heart failure segment dominated the global market in terms of revenue in 2017. The increasing prevalence of heart-related disorders, rising geriatric population, and high demand for effective solutions are some of the major factors contributing to its dominance over the forecast period. According to a study published by NCBI, it is estimated that around 6% to 12% individuals suffer from chronic heart failure across the globe. In addition, as per American Heart Association (AHA), around 5 million people in U.S., have CHF and about 1/3rd of them are undiagnosed owing to lack proper diagnosis facilities which can be reached through adrenoceptor agonist drugs therefore driving its demand globally during this period.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position throughout the forecast period owing to increasing awareness about asthma and COPD, rising healthcare expenditure, and availability of a wide range of branded drugs. In addition, growing R&D activities for development of novel drug molecules is also expected to drive this regional market over the forecast period.
Asia Pacific – which includes emerging countries such as China & India – is anticipated to be one of the fastest-growing regions during the same period owing mainly to increasing prevalence of chronic diseases such as cardiac failure and asthma among all age groups in these countries. Moreover, government initiatives for control & prevention purpose are also contributing towards growth in this region (for instance; National Health Mission 2016). These factors are likely boost overall revenue generation capacity across this region during future years forecasted in’s study’s scope'.
Growth Factors:
- Increasing prevalence of cardiovascular diseases (CVDs) is expected to drive the demand for β adrenoceptor agonists over the forecast period.
- Growing geriatric population is also anticipated to boost the market growth as this population is more susceptible to CVDs.
- Rising awareness about the benefits of β adrenoceptor agonists in prevention and treatment of CVDs is projected to propel market growth during the forecast period.
- Technological advancements in drug delivery systems are likely to provide lucrative opportunities for market players over the next few years.
Scope Of The Report
Report Attributes
Report Details
Report Title
β Adrenoceptor Agonists Market Research Report
By Type
Isoprenaline, Dobutamine, Salbutamol, Terbutaline, Salmeterol, Formoterol, Pirbuterol
By Application
Chronic Heart Failure, Myocardial Infarction, Postoperative Hypotension, Bronchial Asthma, Asthmatic Bronchitis, Emphysema, Others
By Companies
Ivax Pharmaceuticals , Physicians Total Care, Baxter Healthcare , Sanofi, Pfizer, Bedford Laboratories, Novartis, Sterimax, Teligent, AstraZeneca, Hikma Pharmaceuticals, Av Kare, Impax Laboratories, PD-Rx Pharmaceuticals, Athenex Pharmaceutical Division, Teva, Marlex Pharmaceuticals, Lannett Company, West-Ward Pharmaceuticals, United Biomedical, Merck, Mylan
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
138
Number of Tables & Figures
97
Customization Available
Yes, the report can be customized as per your need.
Global β Adrenoceptor Agonists Market Report Segments:
The global β Adrenoceptor Agonists market is segmented on the basis of:
Types
Isoprenaline, Dobutamine, Salbutamol, Terbutaline, Salmeterol, Formoterol, Pirbuterol
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Chronic Heart Failure, Myocardial Infarction, Postoperative Hypotension, Bronchial Asthma, Asthmatic Bronchitis, Emphysema, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Ivax Pharmaceuticals
- Physicians Total Care
- Baxter Healthcare
- Sanofi
- Pfizer
- Bedford Laboratories
- Novartis
- Sterimax
- Teligent
- AstraZeneca
- Hikma Pharmaceuticals
- Av Kare
- Impax Laboratories
- PD-Rx Pharmaceuticals
- Athenex Pharmaceutical Division
- Teva
- Marlex Pharmaceuticals
- Lannett Company
- West-Ward Pharmaceuticals
- United Biomedical
- Merck
- Mylan
Highlights of The β Adrenoceptor Agonists Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Isoprenaline
- Dobutamine
- Salbutamol
- Terbutaline
- Salmeterol
- Formoterol
- Pirbuterol
- By Application:
- Chronic Heart Failure
- Myocardial Infarction
- Postoperative Hypotension
- Bronchial Asthma
- Asthmatic Bronchitis
- Emphysema
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the β Adrenoceptor Agonists Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
u00ceu00b2 Adrenoceptor agonists are medications that work to increase the activity of u00ceu00b2 adrenoceptors in the body. This can lead to increased blood flow and energy levels, which can improve symptoms associated with a number of conditions, including anxiety, depression, and chronic pain.
Some of the major companies in the î² adrenoceptor agonists market are Ivax Pharmaceuticals , Physicians Total Care, Baxter Healthcare , Sanofi, Pfizer, Bedford Laboratories, Novartis, Sterimax, Teligent, AstraZeneca, Hikma Pharmaceuticals, Av Kare, Impax Laboratories, PD-Rx Pharmaceuticals, Athenex Pharmaceutical Division, Teva, Marlex Pharmaceuticals, Lannett Company, West-Ward Pharmaceuticals, United Biomedical, Merck, Mylan.
The ² adrenoceptor agonists market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 β Adrenoceptor Agonists Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 β Adrenoceptor Agonists Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 β Adrenoceptor Agonists Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the β Adrenoceptor Agonists Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global β Adrenoceptor Agonists Market Size & Forecast, 2018-2028
4.5.1 β Adrenoceptor Agonists Market Size and Y-o-Y Growth
4.5.2 β Adrenoceptor Agonists Market Absolute $ Opportunity
Chapter 5 Global β Adrenoceptor Agonists Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 β Adrenoceptor Agonists Market Size Forecast by Type
5.2.1 Isoprenaline
5.2.2 Dobutamine
5.2.3 Salbutamol
5.2.4 Terbutaline
5.2.5 Salmeterol
5.2.6 Formoterol
5.2.7 Pirbuterol
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global β Adrenoceptor Agonists Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 β Adrenoceptor Agonists Market Size Forecast by Applications
6.2.1 Chronic Heart Failure
6.2.2 Myocardial Infarction
6.2.3 Postoperative Hypotension
6.2.4 Bronchial Asthma
6.2.5 Asthmatic Bronchitis
6.2.6 Emphysema
6.2.7 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global β Adrenoceptor Agonists Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 β Adrenoceptor Agonists Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America β Adrenoceptor Agonists Analysis and Forecast
9.1 Introduction
9.2 North America β Adrenoceptor Agonists Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America β Adrenoceptor Agonists Market Size Forecast by Type
9.6.1 Isoprenaline
9.6.2 Dobutamine
9.6.3 Salbutamol
9.6.4 Terbutaline
9.6.5 Salmeterol
9.6.6 Formoterol
9.6.7 Pirbuterol
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America β Adrenoceptor Agonists Market Size Forecast by Applications
9.10.1 Chronic Heart Failure
9.10.2 Myocardial Infarction
9.10.3 Postoperative Hypotension
9.10.4 Bronchial Asthma
9.10.5 Asthmatic Bronchitis
9.10.6 Emphysema
9.10.7 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe β Adrenoceptor Agonists Analysis and Forecast
10.1 Introduction
10.2 Europe β Adrenoceptor Agonists Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe β Adrenoceptor Agonists Market Size Forecast by Type
10.6.1 Isoprenaline
10.6.2 Dobutamine
10.6.3 Salbutamol
10.6.4 Terbutaline
10.6.5 Salmeterol
10.6.6 Formoterol
10.6.7 Pirbuterol
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe β Adrenoceptor Agonists Market Size Forecast by Applications
10.10.1 Chronic Heart Failure
10.10.2 Myocardial Infarction
10.10.3 Postoperative Hypotension
10.10.4 Bronchial Asthma
10.10.5 Asthmatic Bronchitis
10.10.6 Emphysema
10.10.7 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific β Adrenoceptor Agonists Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific β Adrenoceptor Agonists Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific β Adrenoceptor Agonists Market Size Forecast by Type
11.6.1 Isoprenaline
11.6.2 Dobutamine
11.6.3 Salbutamol
11.6.4 Terbutaline
11.6.5 Salmeterol
11.6.6 Formoterol
11.6.7 Pirbuterol
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific β Adrenoceptor Agonists Market Size Forecast by Applications
11.10.1 Chronic Heart Failure
11.10.2 Myocardial Infarction
11.10.3 Postoperative Hypotension
11.10.4 Bronchial Asthma
11.10.5 Asthmatic Bronchitis
11.10.6 Emphysema
11.10.7 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America β Adrenoceptor Agonists Analysis and Forecast
12.1 Introduction
12.2 Latin America β Adrenoceptor Agonists Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America β Adrenoceptor Agonists Market Size Forecast by Type
12.6.1 Isoprenaline
12.6.2 Dobutamine
12.6.3 Salbutamol
12.6.4 Terbutaline
12.6.5 Salmeterol
12.6.6 Formoterol
12.6.7 Pirbuterol
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America β Adrenoceptor Agonists Market Size Forecast by Applications
12.10.1 Chronic Heart Failure
12.10.2 Myocardial Infarction
12.10.3 Postoperative Hypotension
12.10.4 Bronchial Asthma
12.10.5 Asthmatic Bronchitis
12.10.6 Emphysema
12.10.7 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) β Adrenoceptor Agonists Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) β Adrenoceptor Agonists Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) β Adrenoceptor Agonists Market Size Forecast by Type
13.6.1 Isoprenaline
13.6.2 Dobutamine
13.6.3 Salbutamol
13.6.4 Terbutaline
13.6.5 Salmeterol
13.6.6 Formoterol
13.6.7 Pirbuterol
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) β Adrenoceptor Agonists Market Size Forecast by Applications
13.10.1 Chronic Heart Failure
13.10.2 Myocardial Infarction
13.10.3 Postoperative Hypotension
13.10.4 Bronchial Asthma
13.10.5 Asthmatic Bronchitis
13.10.6 Emphysema
13.10.7 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 β Adrenoceptor Agonists Market: Competitive Dashboard
14.2 Global β Adrenoceptor Agonists Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Ivax Pharmaceuticals
14.3.2 Physicians Total Care
14.3.3 Baxter Healthcare
14.3.4 Sanofi
14.3.5 Pfizer
14.3.6 Bedford Laboratories
14.3.7 Novartis
14.3.8 Sterimax
14.3.9 Teligent
14.3.10 AstraZeneca
14.3.11 Hikma Pharmaceuticals
14.3.12 Av Kare
14.3.13 Impax Laboratories
14.3.14 PD-Rx Pharmaceuticals
14.3.15 Athenex Pharmaceutical Division
14.3.16 Teva
14.3.17 Marlex Pharmaceuticals
14.3.18 Lannett Company
14.3.19 West-Ward Pharmaceuticals
14.3.20 United Biomedical
14.3.21 Merck
14.3.22 Mylan
